Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis
Sign Up to like & getrecommendations! Published in 2025 at "British Journal of Haematology"
DOI: 10.1111/bjh.70065
Abstract: Midostaurin, a multikinase/KIT inhibitor, is approved for the treatment of advanced systemic mastocytosis (AdvSM). We evaluated dosing regimens, safety, efficacy and overall survival (OS) of 79 patients from the ‘German Registry on Disorders of Eosinophils… read more here.
Keywords: systemic mastocytosis; response; advanced systemic; modified valent ... See more keywords